Pediatric Vouchers Could Limit Adult Rare Disease Development, FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency expands its critique of voucher incentive that it feels is a strain on agency resources.
You may also be interested in...
Priority Review Vouchers: Does Novartis Have User's Regret?
Stakeholders are sympathetic to FDA's concerns that voucher program requires diversion of precious resources, but some believe it provides substantial drug development incentive, particularly for small companies.
Sanofi Diabetes Franchise Could Get Boost From Retrophin’s Voucher
Priority review ticket might be used on Type 2 diabetes combo LixiLan, expected to be filed later this year.
Gene Therapy: Pediatric Development Could Start Sooner Than Sponsors Think – FDA OTP Director
Nicole Verdun said children could participate in gene therapy clinical trials earlier if the necessary controls are in place.